What LegoChem Biosciences does

LegoChem Biosciences (legal name: LIGACHEM BIOSCIENCES Inc., DBA LigaChemBio) is a South Korea-based clinical-stage biopharmaceutical company founded in 2006 and headquartered in Daejeon. The company is publicly listed on KOSDAQ under ticker 141080 and operates with approximately 101–250 employees. Its stated mission is to develop innovative therapeutics that address unmet medical needs in oncology by linking chemistry with biologics.

The company's technology stack is built on two proprietary platforms: (1) a next-generation Antibody-Drug Conjugate (ADC) platform designed to overcome the limitations of existing ADC technologies through novel linker-payload architectures and targeted delivery, and (2) a Small Molecule platform focused on synthetic drug R&D for next-generation immuno-oncology agents and ADC payloads. Its clinical-stage pipeline includes LCB02A, a Claudin18.2-targeted ADC that received global Phase 1/2 IND approval. Revenue is generated almost entirely through a partnership-driven, licensing-and-co-development model with global pharmaceutical companies — the company has active alliances with Johnson & Johnson Innovative Medicine, Amgen, and Ono Pharma — monetizing via upfront payments, development milestones, and royalties rather than direct product sales.

In January 2024, Orion acquired a 25.73% stake for approximately 548.7 billion KRW (~$413–425M USD), becoming the largest shareholder and incorporating LegoChem as a subsidiary while retaining the existing management team. This capital infusion is funding aggressive R&D aimed at establishing the company as a leading global ADC developer, with operations focused on the Asian market and a growing global clinical footprint.

Name

LegoChem Biosciences

Legal name

LIGACHEM BIOSCIENCES Inc.

Website

https://legochembio.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

101–250 employees

Short description

LegoChem Biosciences (LigaChemBio) is a South Korean clinical-stage biopharmaceutical company that develops next-generation antibody-drug conjugates (ADCs) and small-molecule immuno-oncology drugs, commercializing its pipeline via licensing and co-development partnerships with global pharma including J&J, Amgen, and Ono.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Oncology R&D

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Small-Molecule API Commercial Manufacturing (HLAGAHAB)

Keywords

• Antibody-drug conjugates
• Oncology drug development
• Small molecule immunotherapy
• Biopharmaceutical R&D
• ADC platform technology

Headquarters

HQ city

Daejeon

HQ country

South Korea

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Licensing and Co-development: LegoChem Biosciences generates revenue through licensing agreements and co-development partnerships with global pharmaceutical companies. The company develops proprietary ADC and small molecule drug pipelines and commercializes them through strategic partnerships, including upfront payments, milestone payments, and royalty arrangements.

Go-to-market motion1 record

Marketing channels2 records

Core offering

LegoChem Biosciences is a clinical-stage biopharmaceutical company developing a proprietary next-generation Antibody-Drug Conjugate (ADC) platform and a Small Molecule platform focused on next-generation immunotherapy anticancer agents and ADC payloads. The company conducts drug discovery and clinical development in oncology and monetizes its pipeline primarily through licensing, co-development, and milestone/royalty arrangements with global pharmaceutical partners.

Product overview

LigaChemBio (LegoChem Biosciences) operates as a biopharmaceutical company built on medicinal chemistry expertise. The company has developed two core technology platforms: a next-generation ADC (Antibody-Drug Conjugate) platform and a Small Molecule platform for immunotherapy and ADC payloads. The ADC platform overcomes limitations of existing ADC technologies, while the Small Molecule platform focuses on novel mechanism immunooncology treatments. The company's pipeline includes LCB02A (Claudin18.2-ADC), currently in global Phase 1/2 clinical trials. These platforms and pipeline products work together to address unmet medical needs through targeted cancer therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

• ADC Platform (Antibody-Drug Conjugate)

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Johnson & Johnson Innovative MedicinecoreStrategic or Co-development PartnerLegoChem Biosciences partners with Johnson & Johnson Innovative Medicine for global new drug development through joint research, co-development, and licensing arrangements to accelerate global drug development.
• AmgencoreStrategic or Co-development PartnerLegoChem Biosciences collaborates with Amgen for global new drug development through partnership arrangements, leveraging each company's strengths in biotechnology and pharmaceutical development.
• Ono PharmacoreStrategic or Co-development PartnerLegoChem Biosciences partners with Ono Pharma for global new drug development through joint research, co-development, and licensing to accelerate global drug development in the biotechnology sector.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• ImmunoGen (AbbVie): ADC pioneer (Elahere for ovarian cancer) acquired by AbbVie for ~$10B. Directly comparable to LegoChemBio as a mid-cap ADC pure-play that was acquired by big pharma — providing a relevant M&A precedent and platform benchmark.
• Seagen (Pfizer): Pioneer in ADC technology (Adcetris, Padcev, Tukysa, Tivdak), acquired by Pfizer for ~$43B in 2023. Represents the gold-standard ADC franchise and the primary acquisition template for ADC specialists like LegoChemBio.
• Daiichi Sankyo: Japanese global pharma that has established ADC leadership through Enhertu and datopotamab deruxtecan (with AstraZeneca). Competes with LegoChemBio in the same oncology ADC space but at vastly greater scale and pipeline depth; direct comparable for next-gen ADC platform value.

Direct peers

• ProfoundBio: Clinical-stage ADC company with proprietary linker and payload chemistry, pursued by Genmab's announced acquisition. Direct competitor to LegoChemBio's next-generation ADC positioning and partnership-driven model.
• Tubulis: European ADC platform company developing next-generation linkers and payloads for solid tumor targets. Comparable to LegoChemBio as a platform-focused, partnership-enabled ADC developer targeting improved therapeutic index.
• Bolt Biotherapeutics: Clinical-stage oncology company developing immune-stimulating ADCs (ISACs). Adjacent peer to LegoChemBio — both are platform-based ADC developers pursuing novel conjugation and payload strategies for oncology.
• Pyxis Oncology: Clinical-stage ADC and immuno-oncology developer with multiple partnered programs. Comparable to LegoChemBio's business model of out-licensed assets and platform-driven ADC development.
• Mersana Therapeutics: Clinical-stage biotech developing next-generation ADCs using proprietary linker and payload platforms (Dolasynthen, Immunosynthen). Closely comparable to LegoChemBio in stage, business model (platform licensing), and ADC technology focus.

Others

• WuXi XDC: Leading ADC contract development and manufacturing organization (CDMO) spun out of WuXi Biologics. Comparable as an ecosystem enabler in the ADC value chain — provides infrastructure that LegoChemBio and its peers rely on for ADC manufacturing.

Regional players

• Hansoh Pharmaceutical: Major Chinese pharma with growing ADC pipeline and global out-licensing ambitions. Comparable to LegoChemBio as a regional (Asian) ADC developer pursuing similar oncology targets and international partnership strategies.

Market position

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/legochem-biosciences-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LegoChem Biosciences